<div id="readability-page-1"><p>Meeder Asset Management Inc. increased its holdings in  Elevance Health, Inc. (NYSE:ELV - Free Report) by 31,029.4% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor  owned 15,876 shares of the company's stock after buying an additional 15,825 shares during the period. Meeder Asset Management Inc.'s holdings in Elevance Health were worth $5,130,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Elevance Health</strong> alerts:</span></p></div><ul><li>This ETF Is Proof That the Healthcare Rebound Is Real</li></ul><p>A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in  Elevance Health by 3.2% in the second quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company's stock valued at $8,890,419,000 after purchasing an additional 704,790 shares during the last quarter.  Sanders Capital LLC lifted its stake in shares of  Elevance Health by 24.7% in the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company's stock worth $2,265,773,000 after buying an additional 1,152,440 shares in the last quarter.  Artisan Partners Limited Partnership increased its holdings in  Elevance Health by 9.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company's stock worth $1,429,498,000 after buying an additional 324,399 shares in the last quarter.  Norges Bank purchased a new stake in  Elevance Health during the 2nd quarter valued at $1,148,379,000.  Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of  Elevance Health by 30.7% in the second quarter. The Manufacturers Life Insurance Company now owns 2,076,668 shares of the company's stock worth $807,741,000 after buying an additional 487,579 shares during the last quarter. 89.24% of the stock is owned by institutional investors. </p><h2>Elevance Health Price Performance</h2><p>Elevance Health stock opened at $372.80 on Monday. The company's 50 day moving average is $338.20 and its two-hundred day moving average is $327.98. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The firm has a market cap of $82.85 billion, a PE ratio of 15.24, a price-to-earnings-growth ratio of 1.92 and a beta of 0.51. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. </p><ul><li>Getting Defensive: 3 Dividend Payers Reporting Strong Q3 Earnings</li></ul><p>Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings results on Tuesday, October 21st. The company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.03 by $1.00. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The company had revenue of $50.09 billion for the quarter, compared to analysts' expectations of $49.26 billion. During the same period last year, the firm earned $8.37 earnings per share. Elevance Health's quarterly revenue was up 12.0% on a year-over-year basis.  On average, research analysts expect that  Elevance Health, Inc. will post 33.96 EPS for the current fiscal year. </p><h2>Elevance Health Announces Dividend</h2><p>The business also recently declared a quarterly dividend, which was paid on Friday, December 19th. Stockholders of record on Friday, December 5th were given a dividend of $1.71 per share. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date was Friday, December 5th. Elevance Health's dividend payout ratio (DPR) is presently 27.96%. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>Why Centene Stock Dropped 40% — And Whether It's a Buy Now</li></ul><p>Several brokerages have recently commented on ELV. JPMorgan Chase &amp; Co. raised their price objective on shares of Elevance Health from $384.00 to $394.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, October 28th. Deutsche Bank Aktiengesellschaft  reiterated a &#34;hold&#34; rating and issued a $320.00 price target (down from $332.00) on shares of Elevance Health in a report on Friday, December 19th. Wolfe Research  set a $425.00 price target on Elevance Health and gave the stock an &#34;outperform&#34; rating in a research report on Thursday. Mizuho  set a $413.00 price target on shares of Elevance Health in a research report on Friday. Finally, Morgan Stanley cut their price target on shares of Elevance Health from $359.00 to $352.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Wednesday, December 17th. Thirteen investment analysts have rated the stock with a Buy rating, eleven have issued  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $400.85.</p><p><b>View Our Latest Stock Analysis on Elevance Health</b></p><h2>Elevance Health Profile</h2> (Free Report)<p>Elevance Health, Inc <span>NYSE: ELV<span></span></span> is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.  </p><p>Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Elevance Health</li><li>Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026</li><li>Shots officially fired…</li><li>Do not delete, read immediately</li><li>Trump Planning to Use Public Law 63-43: Prepare Now</li><li>Huge robotics rollout underway</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMVg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Elevance Health Right Now?</h2><p>Before you consider Elevance Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.</p><p>While Elevance Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Meeder Asset Management Inc. significantly increased its stake in Elevance Health, Inc. by 31,029.4% during Q3, acquiring an additional 15,825 shares, bringing its total to 15,876 shares valued at $5.13 million. Other institutional investors, including Vanguard and Sanders Capital, also raised their positions in Elevance Health. The company's stock opened at $372.80, with a market cap of $82.85 billion and a PE ratio of 15.24. Elevance Health reported Q3 earnings of $6.03 per share, exceeding estimates, and declared a quarterly dividend of $1.71 per share.</p>

Meeder Asset Management Inc. Purchases 15,825 Shares of Elevance Health, Inc. $ELV